Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2026-03-11 @ 5:34 AM
Study NCT ID:
NCT02617134
Status:
UNKNOWN
Last Update Posted:
2016-12-06
First Post:
2015-11-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Sponsor:
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Organization:
Study Overview
Official Title:
Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor
Status:
UNKNOWN
Status Verified Date:
2016-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: